Milestone Pharmaceuticals Inc.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
MIST$0.74-3.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Shareholders’ Equity
Condensed Consolidated Statements of Shareholders’ Equit****y (Unaudited)
(in thousands of US dollars, except share data)
| | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Common Shares · · Pre-funded warrants · · · · · · · · · | |||||||||||||||||||
| · · Numberof shares · · Amount · · Numberof warrants · · Amount · · Additionalpaid-incapital · · Accumulateddeficit · · Total | |||||||||||||||||||
| Balance as of December 31, 2024 | | 53,353,984 | | $288,048 | | 12,910,590 | | $53,076 | | $39,568 | | $(367,545) | | $13,147 | |||||
| Transactions during the three-month period ended March 31, 2025 | | | | | | | | | | | | | | | | | | | |
| Net loss | | — | | | — | | — | | | — | | | — | | | (20,761) | | | (20,761) |
| Share-based compensation | | — | | | — | | — | | | — | | | 1,351 | | | — | | | 1,351 |
| Employee stock purchase plan purchases | | 110,289 | | | 140 | | — | | | — | | | — | | | — | | | 140 |
| Balance as of March 31, 2025 | | 53,464,273 | | $288,188 | | 12,910,590 | | $53,076 | | $40,919 | | $(388,306) | | $(6,123) | |||||
| | | | | | | | | | | | | | | | | | | | |
| Balance as of December 31, 2025 | | 106,236,344 | | $352,619 | | 16,412,925 | | $55,649 | | $64,104 | | $(430,603) | | $41,769 | |||||
| Transactions during the three-month period ended March 31, 2026 | | | | | | | | | | | | | | | | | | | |
| Net loss | | — | | | — | | — | | | — | | | — | | | (26,066) | | | (26,066) |
| Share-based compensation | | — | | | — | | — | | | — | | | 1,282 | | | — | | | 1,282 |
| Issuance of common shares, vesting of restricted stock units | | 237,677 | | | 480 | | — | | | — | | | (480) | | | — | | | — |
| Issuance of common shares, net of issuance costs | | 5,526,590 | | | 10,891 | | — | | | — | | | — | | | — | | | 10,891 |
| Exercise of Series A common stock warrants, net of issuance costs | | 5,666,666 | | | 9,529 | | — | | | — | | | (1,539) | | | — | | | 7,990 |
| Employee stock purchase plan purchases | | 127,140 | | | 183 | | — | | | — | | | — | | | — | | | 183 |
| Balance as of March 31, 2026 | | 117,794,417 | | $373,702 | | 16,412,925 | | $55,649 | | $63,367 | | $(456,669) | | $36,049 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.